Medicating patients during extracorporeal membrane oxygenation: The evidence is building

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Dzierba, Amy L ^a   Abrams, Darryl ^b   Brodie, Daniel ^b  

^a Department of Medicine   (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CARBAPENEM; CASPOFUNGIN; CEPHALOSPORIN; CIPROFLOXACIN; DEXMEDETOMIDINE; FENTANYL; MEROPENEM; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PROPOFOL; SEDATIVE AGENT; VANCOMYCIN; ANALGESIC AGENT; HYPNOTIC SEDATIVE AGENT;

ANALGESIA; CONTINUOUS INFUSION; CRITICAL ILLNESS; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; EX VIVO STUDY; EXTRACORPOREAL OXYGENATION; GASTROINTESTINAL TRACT; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEART FAILURE; HEPATOBILIARY SYSTEM; HUMAN; HYDROPHILICITY; IONIZATION; LOADING DRUG DOSE; LUNG TRANSPLANTATION; MEDICATION THERAPY MANAGEMENT; MOLECULAR WEIGHT; MULTIPLE ORGAN FAILURE; OXYGEN CONSUMPTION; PATIENT CARE; PROTEIN BINDING; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; SEDATION; VOLUME OF DISTRIBUTION; PHARMACOKINETICS;

ANALGESICS; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPNOTICS AND SEDATIVES; PHARMACOKINETICS;

EID: 85015644148     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1644-y     Document Type: Review

References (45)

1. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med. 2011;365:1905-14.
2. Paden ML, Conrad SA, Rycus PT, Thiagarajan RR, Registry ELSO. Extracorporeal life support organization registry report 2012. Asaio J. 2012;59:202-10.
3. Karagiannidis C, Brodie D, Strassmann S, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med. 2016;42:889-96.
4. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840-51.
5. Shekar K, Fraser JF, Smith MT, et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741.
6. Shekar K, Roberts JA, McDonald CI, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194.
7. Preston TJ, Ratliff TM, Gomez D, et al. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol. 2010;42:199-202.
8. Preston TJ, Hodge AB, Riley JB, et al. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234-7.
9. Rosen DA, Rosen KR, Silvasi DL. In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth. 1990;4:332-5.
10. Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109-16.
11. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion. 2000;15:21-6.
12. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20:309-15.
13. Unger JK, Kuehlein G, Schroers A, Gerlach JC, Rossaint R. Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research - limits and progress. Biomaterials. 2001;22:2031-7.
14. Shekar K, Roberts JA, Mcdonald CI, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19:164.
15. Shekar K, Roberts JA, Barnett AG, et al. Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. Crit Care. 2015;19:437.
16. Poole SK, Poole CF. Separation methods for estimating octanol-water partition coefficients. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;797:3-19.
17. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the ICU. Crit Care Med. 2013;41:263-306.
18. Wagner D, Pasko D, Phillips K, et al. In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation. Perfusion. 2013;28:40-6.
19. Lemaitre F, Hasni N, Leprince P, et al. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care. 2015;19:40.
20. Shekar K, Roberts JA, Ghassabian S, et al. Sedation during extracorporeal membrane oxygenation - why more is less. Anaesth Intensive Care. 2012;40:1067-9.
21. Shekar K, Roberts JA, Mullany DV, et al. Increased sedation requirements in patients receiving extracorporeal membrane oxygenation for respiratory and cardiorespiratory failure. Anaesth Intensive Care. 2012;40:648-55.
22. DeGrado JR, Hohlfelder B, Ritchie BM, Anger KE, Reardon DP, Weinhouse GL. Evaluation of sedatives, analgesics, and neuromuscular blocking agents in adults receiving extracorporeal membrane oxygenation. J Crit Care. 2016;37:1-6.
23. Der Nigoghossian C, Dzierba AL, Etheridge J, et al. Effect of extracorporeal membrane oxygenation use on sedative requirements in patients with severe acute respiratory distress syndrome. Pharmacotherapy. 2016;36:607-16.
24. Tellor B, Shin N, Graeta TJ, Avidan MS. Ketamine infusion for patients receiving extracorporeal membrane oxygenation support: a case series. F1000Res. 2015;4:16.
25. Floroff CK, Hassig TB, Cochran JB, Mazur JE. High-dose sedation and analgesia during extracorporeal membrane oxygenation: A focus on the adjunctive use of ketamine. J Pain Palliat Care Pharmacother. 2016;30:36-40.
26. Dzierba AL, Brodie D, Bacchetta M, et al. Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation. Intensive Care Med. 2016;42:1822-3.
27. Buscher H, Vaidiyanathan S, Al-Soufi S, et al. Sedation practice in veno-venous extracorporeal membrane oxygenation: an international survey. ASAIO J. 2013;59:636-41.
28. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637.
29. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96.
30. Donadello K, Roberts JA, Cristallini S, et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care. 2014;18:632.
31. De Rosa FG, Corcione S, Baietto L, et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents. 2013;41:590-1.
32. Gélisse E, Neuville M, de Montmollin E, et al. Extracoporeal membrane oxygenation (ECMO) does not impact on amikacin pharmacokinetics: a case-control study. Intensive Care Med. 2016;42:946-8.
33. Shekar K, Roberts JA, Ghassabian S, et al. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern? J Antimicrob Chemother. 2013;68:726-7.
34. Shekar K, Fraser JF, Taccone FS, et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care. 2014;18:565.
35. Donadello K, Antonucci E, Cristallini S, et al. Beta-lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. Int J Antimicrob Agents. 2015;45:278-82.
36. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;35:606-8.
37. Turner RB, Rouse S, Elbarbry F, et al. Azithromycin pharmacokinetics in adults with acute respiratory distress syndrome undergoing treatment with extracorporeal-membrane oxygenation. Ann Pharmacother. 2016;50:72-3.
38. Veinstein A, Debouverie O, Grégoire N, et al. Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics. J Antimicrob Chemother. 2012;67:1047-8.
39. Lemaitre F, Luyt CE, Roullet-Renoleau F, et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit. 2012;34:171-5.
40. Mulla H, Peek GJ, Harvey C, et al. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anesth Intensive Care. 2013;41:66-73.
41. Eyler RF, Heung M, Pleva M, et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy. 2012;32:1061-9.
42. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33:1018-24.
43. Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2009;63:767-70.
44. Shekar K, Roberts JA, Welch S, et al. ASAP ECMO: Antibiotic, sedative and analgesic pharmacokinetics during extracorporeal membrane oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol. 2012;12:29.
45. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101-11.